Introduction {#s1}
============

Fluoroquinolones, together with extended-spectrum cephalosporins, are the treatment of choice for nontyphoid salmonellosis, as stable resistance to the most common members of different families of antimicrobial agents (ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline) has developed during the 1990s with the epidemic *Salmonella enterica* serovar Typhimurium phage type DT104 (Cloeckaert and Schwarz, [@B9]). Emerging resistance to fluoroquinolones in *Salmonella* spp. has been reported for both human and animal cases and is thus threatening to become a serious public health problem (Cloeckaert and Chaslus-Dancla, [@B8]; Piddock, [@B18]; Velge et al., [@B19]; Giraud et al., [@B11]). Of particular concern is the international spread of ciprofloxacin-resistant serovar Kentucky ST198 (Le Hello et al., [@B15]). This clone is not only highly resistant to ciprofloxacin but also multidrug-resistant (MDR) due to the presence of the *Salmonella* genomic island 1 (SGI1) carrying a multiple antibiotic resistance gene cluster, mostly variant SGI1-K carrying another resistance gene cluster (Doublet et al., [@B10]; Le Hello et al., [@B15]). SGI1 was initially identified in MDR serovar Typhimurium DT104 (Boyd et al., [@B6]), but nor the MDR serovar Typhimurium DT104 clone neither other MDR *S. enterica* serovars carrying SGI1 or variants of it, have to our knowledge been reported to display this high-level ciprofloxacin resistance.

In *Salmonella* spp., quinolone/fluoroquinolone resistance is mostly attributed to point mutations in the quinolone resistance-determining regions (QRDRs) of the target genes *gyrA, gyrB, parC*, and *parE*. For the *gyrA* gene, coding for the A subunit of DNA gyrase, mutations resulting in amino acid changes at Ser83 (to Phe, Tyr, or Ala) or at Asp87 (to Gly, Asn, or Tyr) are the most frequently observed in nalidixic acid-resistant strains (Cloeckaert and Chaslus-Dancla, [@B8]; Piddock, [@B18]; Velge et al., [@B19]; Giraud et al., [@B11]). High-level fluoroquinolone resistance has been reported in several *S. enterica* serovars (Choleraesuis, Schwarzengrund, Typhimurium) and is essentially due to the combination of several target gene mutations of which the most frequent are double mutations resulting in modifications of both residues 83 and 87 of GyrA together with one mutation leading to the amino acid change Ser80Ile in the ParC subunit of topoisomerase IV (Baucheron et al., [@B5], [@B3]; Chu et al., [@B7]). In addition two main other mechanisms have been reported consisting of active afflux mediated by the chromosomally-encoded AcrAB-TolC efflux system and target protection by Qnr proteins which are mostly encoded by plasmids acquired by horizontal transfer (Giraud et al., [@B11]). However, according to the literature over 15 years, these mechanisms appear less frequently and thus from an epidemic point of view seem of lesser importance than multiple target gene mutations to reach high-level ciprofloxacin resistance and compromise treatment.

In the case of ciprofloxacin resistance in serovar Kentucky ST198, three combinations of multiple target modifications, acquired in a possible sequential way, have been reported consisting of a first GyrA Ser83Phe modification, followed by three different situations of a second GyrA modification at position 87, i.e., Asp87Asn, Asp87Gly, or Asp87Tyr, and finally the ParC modification Ser80Ile (Le Hello et al., [@B15]). Qnr proteins have not been reported yet as additional mechanism for this epidemic clone, and active efflux has been suspected in a previous study due to a moderate increase of production in some isolates of the AcrA protein belonging to the AcrAB-TolC efflux system (Weill et al., [@B20]).

In the present study we assessed the frequency of enhanced efflux by AcrAB-TolC in a subset of serovar Kentucky ST198 strains of the 2000--2005 period of the epidemic. In case of significant increased production of AcrAB-TolC we investigated more deeply the regulatory mechanisms behind this overproduction, in particular the involvement of the *ram, sox*, and *mar* regulatory loci (Abouzeed et al., [@B1]; Kehrenberg et al., [@B14]). Among these loci, the *ramRA* locus appears to be the most important in regulating AcrAB-TolC expression in *Salmonella* spp. (Abouzeed et al., [@B1]; Kehrenberg et al., [@B14]). *ramR* encodes a repressor protein (RamR) belonging to the TetR family of repressor proteins, and has been shown to be the local repressor protein of *ramA* transcription (Abouzeed et al., [@B1]; Baucheron et al., [@B4]); while *ramA* encodes a transcriptional activator protein (RamA) belonging to the AraC/XylS family of regulatory proteins (Nikaido et al., [@B16]). The latter is involved in upregulating expression of the AcrAB-TolC system (Nikaido et al., [@B16]). Several mutations in *ramR* or its binding site upstream of *ramA*, affecting expression of this efflux system, have been detected in clinical isolates of serovar Typhimurium and of minor serovars Hadar, Infantis, Livingstone, or Schwarzengrund (Abouzeed et al., [@B1]; Kehrenberg et al., [@B14]; Hentschke et al., [@B13]; Akiyama and Khan, [@B2]).

Materials and methods {#s2}
=====================

The 27 serovar Kentucky ST198 strains selected for this study are shown in Table [1](#T1){ref-type="table"}. Bacterial isolates were selected for this study, based on their evolutionary history following the emergence of target gene mutations initially in *gyrA* at the commencement of the epidemic in 2000--2002, followed by isolates with additional mutations (in *gyrA* and *parC*) toward the end in 2002--2005 and which demonstrated a higher MIC toward ciprofloxacin. An additional criterion for selection consisted of the differences observed in ciprofloxacin MICs suggestive for another resistance mechanism than target gene mutation. MICs were determined as described previously (Baucheron et al., [@B5], [@B3]). SGI1 detection and characterization were performed as described previously (Boyd et al., [@B6]; Doublet et al., [@B10]). Efflux pump production was assessed by Dot blot using an anti-AcrA polyclonal antibody as described previously (Abouzeed et al., [@B1]). Occurrence of mutations affecting *acrAB* and *tolC* expression was determined by PCR and sequencing the regulatory regions *ramR-ramA, acrR-acrA, marC*-marO-*marR-marA, soxS-soxR*, and *acrS-acrE* using primers listed in Table [2](#T2){ref-type="table"}. Transcription levels of *ramA, acrA*, and *tolC* were determined by qRT-PCR as described previously (Giraud et al., [@B12]).

###### 

***Salmonella enterica* serovar Kentucky ST198 strains analyzed in this study**.

  **Strain**   **Country**       **Year of isolation**   **Antimicrobial resistance profile**   **SGI1**       **PFGE type**   **CIP MIC (μg/ml)**   **Substitution(s) in the QRDR of:**   **Mutation(s) in efflux pump regulatory regions**   **AcrA production ratio**   
  ------------ ----------------- ----------------------- -------------------------------------- -------------- --------------- --------------------- ------------------------------------- --------------------------------------------------- --------------------------- ---
  00 1059      Egypt             2000                    AMX NAL                                \+ (SGI1-P1)   XKEN-1a         0.125                 S83F                                  None                                                                            3
  01 2100      Egypt             2001                    AMX STR SPT GEN SUL TET NAL            \+ (SGI1-K1)   XKEN-1a         0.125                 S83F                                  None                                                --                          2
  02 2818      Egypt             2002                    AMX STR SPT GEN SUL TET NAL            \+             XKEN-1i         0.5                   S83F                                  None                                                \+ *(ramR)*                 5
  02 2691      Egypt             2002                    AMX STR SPT GEN SUL TET NAL            \+ (SGI1-K3)   XKEN-1a         0.125                 S83F                                  None                                                --                          1
  02 8051      Egypt             2002                    AMX STR SPT GEN SUL TET NAL            \+             XKEN-1a         0.25                  S83F                                  None                                                --                          1
  02 8141      Egypt             2002                    AMX STR SPT GEN SUL TET NAL            \+ (SGI1-K1)   XKEN-1m         0.5                   S83F                                  None                                                \+ (*ramR*)                 5
  02 9866      Egypt             2002                    AMX STR SPT GEN SUL TET NAL CIP        \+             XKEN-1a         8                     S83F, D87N                            S80I                                                --                          2
  03 9270      India             2003                    NAL                                    --             XKEN-2d         0.125                 S83F                                  None                                                --                          1
  04 2049      Egypt             2004                    NAL CIP                                \+             XKEN-1b         8                     S83F, D87G                            S80I                                                --                          2
  04 4567      Egypt             2004                    AMX STR SPT GEN SUL TET NAL CIP        \+ (SGI1-K1)   XKEN-1g         4                     S83F, D87G                            S80I                                                --                          2
  04 6248      Egypt             2004                    STR SPT GEN SUL TET NAL CIP            \+             XKEN-1a         8                     S83F, D87G                            S80I                                                --                          1
  04 7734      Egypt             2004                    AMX STR SPT GEN SUL TET NAL            \+ (SGI1-K1)   XKEN-1h         0.5                   S83F                                  None                                                --                          1
  04 8262      Egypt             2004                    STR SPT GEN SUL NAL CIP                \+ (SGI1-K5)   XKEN-1a         8                     S83F, D87N                            S80I                                                --                          1
  04 9384      Egypt             2004                    AMX STR SPT GEN SUL TET NAL CIP        \+             XKEN-1g         4                     S83F, D87G                            S80I                                                --                          1
  05 0490      Egypt             2005                    STR SPT GEN SUL TET NAL CIP            \+             XKEN-1a         4                     S83F, D87G                            S80I                                                --                          2
  05 0520      Egypt             2005                    AMX NAL CIP                            \+ (SGI1-P2)   XKEN-1a         4                     S83F, D87Y                            S80I                                                --                          1
  05 1016      Kenya             2005                    NAL CIP                                \+ (SGI1-Q2)   XKEN-1a         4                     S83F, D87Y                            S80I                                                --                          1
  05 1199      Egypt             2005                    STR SPT GEN SUL NAL CIP                \+ (SGI1-Q3)   XKEN-1a         4                     S83F, D87G                            S80I                                                --                          1
  05 2131      Egypt             2005                    AMX NAL CIP                            \+ (SGI1-Q1)   XKEN-1a         4                     S83F, D87N                            S80I                                                --                          3
  05 2354      Kenya/ Tanzania   2005                    AMX STR SPT GEN SUL TET NAL CIP        \+             XKEN-1c         8                     S83F, D87Y                            S80I                                                --                          3
  05 3290      Egypt             2005                    AMX STR SPT GEN SUL TET NAL CIP        \+             XKEN-1c         4                     S83F, D87G                            S80I                                                --                          1
  05 3883      Kenya/ Tanzania   2005                    AMX STR SPT GEN SUL TET NAL CIP        \+             XKEN-1d         4                     S83F, D87Y                            S80I                                                --                          2
  05 4680      Sudan             2005                    STR SPT GEN SUL TET NAL CIP            \+ (SGI1-K4)   XKEN-1l         4                     S83F, D87G                            S80I                                                --                          2
  05 7714      Unknown           2005                    AMX NAL CIP                            \+             XKEN-1b         4                     S83F, D87N                            S80I                                                --                          2
  05 8560      Tunisia           2005                    AMX STR SPT GEN SUL TET NAL CIP        \+             XKEN-1d         16                    S83F, D87N                            S80I                                                \+ (*ramR*)                 6
  05 236       Egypt             2005                    AMX NAL CIP                            \+             XKEN-1c         4                     S83F, D87N                            S80I                                                --                          1
  05 5111      Libya             2005                    AMX SUL TET NAL CIP                    \+ (SGI1-K2)   XKEN-1a         4                     S83F, D87N                            S80I                                                --                          1

###### 

**Primers used for PCRs**.

  **Primer used and target region**   **Primer**   **Nucleotide position relative to the LT2 strain genome**[^**\***^](#TN1){ref-type="table-fn"}   **Oligonucleotide sequences(s) (5′ to 3′)**   **Size (bp)**   **Annealing temp (°)C**   **References**
  ----------------------------------- ------------ ------------------------------------------------------------------------------------------------ --------------------------------------------- --------------- ------------------------- -------------------------
  **DETECTION OF MUTATIONS**                                                                                                                                                                                                                
  *ramR-ramA*                         ram5         638085                                                                                           TCGGTAAAAGGCAGTTCCAG                          958             60                        This study
                                      ramA6        639042                                                                                           GTCGATAACCTGAGCGGAAA                                                                    
  *acrR-acrA*                         acrR1        533463                                                                                           CAGTGGTTCCGTTTTTAGTG                          992             58                        Olliver et al., [@B17]
                                      acrR2        534454                                                                                           ACAGAATAGCGACACAGAAA                                                                    
  *marC*-marO*-marR-marA*             marR1        1597459                                                                                          CAGTGTTGCGTCTGGACATC                          787             60                        This study
                                      marR2        1598245                                                                                          GCTAACGGGAGCAGTACGAC                                                                    
  *soxS-soxR*                         sox1         4503970                                                                                          CTACAGGCGGTGACGGTAAT                          915             60                        This study
                                      sox2         4504884                                                                                          CGGCGCTTTAGTTTTAGGTG                                                                    
  *acrS-acrE*                         acrS1        3560054                                                                                          TTGGCATTAATTGCCTCACA                          1094            62                        This study
                                      acrS2        3561128                                                                                          ATGATGAATGAGGGCAGGAG                                                                    
  **qRT-PCR**                                                                                                                                                                                                                               
  *gmk*                               gmk-f        3933294                                                                                          TTGGCAGGGAGGCGTTT                             62              60                        Baucheron et al., [@B4]
                                      gmk-r        3933355                                                                                          GCGCGAAGTGCCGTAGTAAT                                                                    
  *gyrB*                              gyrB-f       4040275                                                                                          TCTCCTCACAGACCAAAGATAAGCT                     81              60                        Baucheron et al., [@B4]
                                      gyrB-r       4040195                                                                                          CGCTCAGCAGTTCGTTCATC                                                                    
  *rrs*                               rrs-f        NA[^\*\*^](#TN2){ref-type="table-fn"}                                                            CCAGCAGCCGCGGTAAT                             57              60                        Baucheron et al., [@B4]
                                      rrs-r        NA[^\*\*^](#TN2){ref-type="table-fn"}                                                            TTTACGCCCAGTAATTCCGATT                                                                  
  *ramA*                              ramA-f       639180                                                                                           GCGTGAACGGAAGCTAAAAC                          167             60                        Baucheron et al., [@B4]
                                      ramA-r       639346                                                                                           GGCCATGCTTTTCTTTACGA                                                                    
  *acrA*                              acrA-f       533120                                                                                           GAAACCGCACGTATCAACCT                          220             60                        Baucheron et al., [@B4]
                                      acrA-r       532901                                                                                           CCTGTTTCAGCGAACCATTT                                                                    
  *tolC*                              tolC-f       3349107                                                                                          GCCCGTGCGCAATATGAT                            67              60                        Baucheron et al., [@B4]
                                      tolC-r       3349173                                                                                          CCGCGTTATCCAGGTTGTTG                                                                    

GenBank NC_003197.1.

NA: Not Applicable due to the number of copies of this gene in Salmonella.

Results and discussion
======================

As shown in the Table [1](#T1){ref-type="table"} most of the strains selected carried SGI1 or variants of it and were thus MDR. They were all from human cases in France who acquired their infection during travel to Africa or India. As assessed by Dot blot, most of the strains (*n* = 24) did not show significant increased production of AcrA relative to susceptible serovar Kentucky reference strain 98K (AcrA production ratios from 1 to 2; Table [1](#T1){ref-type="table"}). Relative to strain 98K, three strains showed a 3-fold increased AcrA production, and more suggestive for increased active efflux three strains a 5- to 6-fold increased production of AcrA (Table [1](#T1){ref-type="table"}). Among these regulatory regions, mutations were detected only in the *ramR* open reading frame and in only three strains of this study (Table [3](#T3){ref-type="table"}). The mutations were distinct frame shift mutations and consisted of a GATC duplication for strain 02-2818, a G insertion for strain 05-8560, and a 91 bp deletion for strain 02-8141 (Figure [1](#F1){ref-type="fig"}). The role of these mutations in upregulating *acrAB* and *tolC* expression, and consecutive enhanced efflux-mediated resistance, was further assessed by: (i) complementing with the wild-type *ramR* gene (using plasmid pRamR Abouzeed et al., [@B1]); (ii) determining the MICs of ciprofloxacin and unrelated antibiotic florfenicol shown to be substrate of AcrAB-TolC (Baucheron et al., [@B5]); and (iii) measuring expression of *ramA, acrA*, and *tolC* by qRT-PCR (Giraud et al., [@B12]). The results shown in Table [3](#T3){ref-type="table"} are in agreement with data published previously for other *S. enterica* serovars (Abouzeed et al., [@B1]; Kehrenberg et al., [@B14]), i.e. *ramR* mutations observed account for a 2- to 4-fold increased resistance level by active efflux through enhanced expression of AcrAB-TolC. As also observed in previous studies, the effect of such mutations on *ramA* transcription level was significantly higher than on *acrA or tolC* transcription levels. It is somehow expected considering the direct local repressor activity of RamR on *ramA* transcription and the distant RamA transcriptional activator activity on *acrAB* and *tolC* (Abouzeed et al., [@B1]; Baucheron et al., [@B4]; Giraud et al., [@B12]).

###### 

**Characteristics of the *Salmonella enterica* serovar Kentucky ST198 strains carrying *ramR* mutations**.

  **Strain**             **Source**   **Geographic origin**   **Antimicrobial resistance profile**[^**a**^](#TN3){ref-type="table-fn"}   **PFGE type**   **SGI1 (variant)**[^**b**^](#TN4){ref-type="table-fn"}   **MIC of indicated antibiotic (μg/ml)**   **Substitution(s) in the QRDR of:**   **Mutation in *ramR***   **Transcription levels of:**                                                           
  ---------------------- ------------ ----------------------- -------------------------------------------------------------------------- --------------- -------------------------------------------------------- ----------------------------------------- ------------------------------------- ------------------------ ------------------------------ ------ --------------------------------- ------- ------ -----
  **MDR STRAINS**                                                                                                                                                                                                                                                                                                                                                                                                 
  05-8560                Human        Tunisia                 AMX STR SPT GEN SUL TET NAL CIP                                            XKEN-1d         \+ (Ks)                                                  \>1024                                    16                                    16                       S83F, D87Y                     S80I   1 bp insertion (position 506)     24.6    7.2    2.6
  05-8560(pRamR)                                                                                                                                                                                                  \>1024                                    4                                     4                                                                                                2.4     1.7    1.7
  02-8141                Human        Egypt                   AMX STR SPT GEN SUL TET NAL                                                XKEN-1m         \+ (K1)                                                  512                                       0.50                                  16                       S83F                           --     91 bp insertion (position 42)     106.1   10.4   7.8
  02-8141(pRamR)                                                                                                                                                                                                  512                                       0.125                                 8                                                                                                1.6     1.1    1.2
  02-2818                Human        Egypt                   AMX STR SPT GEN SUL TET NAL                                                XKEN-1i         \+ (Ks)                                                  512                                       0.50                                  16                       S83F                           --     4 bp duplication (position 508)   29.1    5.3    4.7
  02-2818(pRamR)                                                                                                                                                                                                  256                                       0.25                                  4                                                                                                1.9     0.9    1.6
  02-9866                Human        Egypt                   AMX STR SPT GEN SUL TET NAL CIP                                            XKEN-1a         \+ (Ks)                                                  \>1024                                    8                                     4                        S83F, D87N                     S80I   --                                2.9     1.2    1.6
  02-9866(pRamR)                                                                                                                                                                                                  \>1024                                    4                                     4                                                                                                1.8     1.6    2.4
  **REFERENCE STRAIN**                                                                                                                                                                                                                                                                                                                                                                                            
  98K                    Chicken      USA                     Susceptible                                                                XKEN-4          --                                                       1                                         0.004                                 2                        --                             --     --                                1.0     1.0    1.0
  98K(pRamR)                                                                                                                                                                                                      1                                         0.004                                 2                                                                                                2.1     1.3    1.5

AMX, amoxycillin; STR, streptomycin; SPT, spectinomycin; GEN, gentamicin; SUL, sulfonamides; TET, tetracycline; NAL, nalidixic acid; CIP, ciprofloxacin.

Ks: subgroup of SGI1-K.

FFC, florfenicol.

![**Mutations detected in *the ramR*-*ramA* region relative to the genome sequence of *S. enterica* serovar Kentucky strain CDC 191 (GenBank: ABEI01000007.1)**.](fmicb-04-00213-g0001){#F1}

Non-target mutations as assessed in this study confirm they are infrequent in *Salmonella* spp. but seem nevertheless mostly restricted to the *ram* regulatory region. Most mutations in the *ramR*-*ramA* region reported to date, as also shown in this study, are distinct and found in single isolates. To our knowledge only independent isolates of the epidemic ciprofloxacin-resistant serovar Typhimurium DT204 clone from the 1990s have been shown to carry the same mutation in *ramR* consisting of an insertion by an IS*1* element (Abouzeed et al., [@B1]). We may nevertheless expect that the further global spread of ciprofloxacin-resistant serovar Kentucky ST198 and its resistance evolution will possibly, like in the case of serovar Typhimurium DT204, result in successful *ramR*-mutation-carrying subclones.
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